195 related articles for article (PubMed ID: 24332498)
1. Targeting molecular pathways in endometrial cancer: a focus on the FGFR pathway.
Lee PS; Secord AA
Cancer Treat Rev; 2014 May; 40(4):507-12. PubMed ID: 24332498
[TBL] [Abstract][Full Text] [Related]
2. Small molecule inhibition of fibroblast growth factor receptors in cancer.
Liang G; Chen G; Wei X; Zhao Y; Li X
Cytokine Growth Factor Rev; 2013 Oct; 24(5):467-75. PubMed ID: 23830577
[TBL] [Abstract][Full Text] [Related]
3. Targeting fibroblast growth factor pathways in endometrial cancer.
Winterhoff B; Konecny GE
Curr Probl Cancer; 2017; 41(1):37-47. PubMed ID: 28041631
[TBL] [Abstract][Full Text] [Related]
4. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J
Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459
[TBL] [Abstract][Full Text] [Related]
5. Rationale for targeting fibroblast growth factor receptor signaling in breast cancer.
André F; Cortés J
Breast Cancer Res Treat; 2015 Feb; 150(1):1-8. PubMed ID: 25677745
[TBL] [Abstract][Full Text] [Related]
6. Targeting FGFR Signaling in Cancer.
Touat M; Ileana E; Postel-Vinay S; André F; Soria JC
Clin Cancer Res; 2015 Jun; 21(12):2684-94. PubMed ID: 26078430
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic agents in advanced, persistent or recurrent endometrial cancer: a novel treatment option.
Gadducci A; Sergiampietri C; Guiggi I
Gynecol Endocrinol; 2013 Sep; 29(9):811-6. PubMed ID: 23767831
[TBL] [Abstract][Full Text] [Related]
8. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
Gozgit JM; Squillace RM; Wongchenko MJ; Miller D; Wardwell S; Mohemmad Q; Narasimhan NI; Wang F; Clackson T; Rivera VM
Cancer Chemother Pharmacol; 2013 May; 71(5):1315-23. PubMed ID: 23468082
[TBL] [Abstract][Full Text] [Related]
9. Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies.
Gadducci A; Cosio S; Genazzani AR
Crit Rev Oncol Hematol; 2006 Jun; 58(3):242-56. PubMed ID: 16436330
[TBL] [Abstract][Full Text] [Related]
10. Proliferation of poorly differentiated endometrial cancer cells through autocrine activation of FGF receptor and HES1 expression.
Mori M; Mori T; Yamamoto A; Takagi S; Ueda M
Hum Cell; 2019 Jul; 32(3):367-378. PubMed ID: 30963412
[TBL] [Abstract][Full Text] [Related]
11. Markers for individualised therapy in endometrial carcinoma.
Salvesen HB; Haldorsen IS; Trovik J
Lancet Oncol; 2012 Aug; 13(8):e353-61. PubMed ID: 22846840
[TBL] [Abstract][Full Text] [Related]
12. [FGF/FGFR blockade: New insights in endometrial cancer].
Flippot R; Vignot S
Bull Cancer; 2015 Dec; 102(12):964-5. PubMed ID: 26617116
[No Abstract] [Full Text] [Related]
13. Targeting fibroblast growth factor receptor pathway in breast cancer.
Criscitiello C; Esposito A; De Placido S; Curigliano G
Curr Opin Oncol; 2015 Nov; 27(6):452-6. PubMed ID: 26397764
[TBL] [Abstract][Full Text] [Related]
14. Targeting the mTOR/4E-BP pathway in endometrial cancer.
Korets SB; Czok S; Blank SV; Curtin JP; Schneider RJ
Clin Cancer Res; 2011 Dec; 17(24):7518-28. PubMed ID: 22142830
[TBL] [Abstract][Full Text] [Related]
15. Resistance to chemotherapy and hormone therapy in endometrial cancer.
Chaudhry P; Asselin E
Endocr Relat Cancer; 2009 Jun; 16(2):363-80. PubMed ID: 19190080
[TBL] [Abstract][Full Text] [Related]
16. FGFR Signaling as a Target for Lung Cancer Therapy.
Desai A; Adjei AA
J Thorac Oncol; 2016 Jan; 11(1):9-20. PubMed ID: 26762735
[TBL] [Abstract][Full Text] [Related]
17. Targeting fibroblast growth factor receptor signaling in hepatocellular carcinoma.
Cheng AL; Shen YC; Zhu AX
Oncology; 2011; 81(5-6):372-80. PubMed ID: 22269894
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic targeting of the TNF superfamily: a promising treatment for advanced endometrial adenocarcinoma.
Thangaraju S; Subramani E; Chakravarty B; Chaudhury K
Gynecol Oncol; 2012 Nov; 127(2):426-32. PubMed ID: 22885470
[TBL] [Abstract][Full Text] [Related]
19. FGFR-targeted therapeutics for the treatment of breast cancer.
De Luca A; Frezzetti D; Gallo M; Normanno N
Expert Opin Investig Drugs; 2017 Mar; 26(3):303-311. PubMed ID: 28121208
[TBL] [Abstract][Full Text] [Related]
20. Developments in the systemic treatment of endometrial cancer.
Mountzios G; Pectasides D; Bournakis E; Pectasides E; Bozas G; Dimopoulos MA; Papadimitriou CA
Crit Rev Oncol Hematol; 2011 Sep; 79(3):278-92. PubMed ID: 20833559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
